Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance

Immunotherapy

Volumn 7, Issue 4, 2015, Pages 399-410

  Pinelli, David F ^a   Ford, Mandy L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

CD40; CD40L; costimulation; Fc receptor; thromboembolism; transplantation

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; FC RECEPTOR; MONOCLONAL ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOEMBOLISM; TRANSPLANTATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; ORGAN TRANSPLANTATION; PROCEDURES; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD40 LIGAND; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; RECEPTOR CROSS-TALK; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

EID: 84928806234     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.1     Document Type: Review

References (82)

1. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann. Rev. Immunol. 16, 111-135 (1998).
2. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl Acad. Sci. USA 89(14), 6550-6554 (1992).
3. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180(4), 1263-1272 (1994).
4. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184(2), 747-752 (1996).
5. Liu D, Ferrer IR, Konomos M, Ford ML. Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo. J. Immunol. 191(4), 1957-1964 (2013).
6. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381(6581), 434-438 (1996).
7. Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl Acad. Sci. USA 92(21), 9560-9564 (1995).
8. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5(6), 686-693 (1999).
9. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv. Exp. Med. Biol. 647, 8-36 (2009).
10. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6(2), 114 (2000).
11. Buhler L, Alwayn IP, Appel JZ 3rd, Robson SC, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 71(3), 491 (2001).
12. Knosalla C, Gollackner B, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism revisited. Transplantation 74(3), 416-417 (2002).
13. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667), 591-594 (1998).
14. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med. 8(3), 247-252 (2002).
15. Zirlik A, Maier C, Gerdes N et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115(12), 1571-1580 (2007).
16. Wolf D, Hohmann JD, Wiedemann A et al. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice. Circ. Res. 109(11), 1269-1279 (2011).
17. Ankersmit HJ, Roth GA, Moser B et al. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am. J. Transplant. 3(6), 754-759 (2003).
18. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96(1), 182-187 (2000).
19. Langer F, Ingersoll SB, Amirkhosravi A et al. The role of CD40 in CD40L-and antibody-mediated platelet activation. Thromb. Haemost. 93(6), 1137-1146 (2005).
20. Robles-Carrillo L, Meyer T, Hatfield M et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185(3), 1577-1583 (2010).
21. Roth GA, Zuckermann A, Klepetko W et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 78(8), 1238-1239; author reply 1239 (2004).
22. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J. Immunol. 175(2), 771-779 (2005).
23. Van Kooten C, Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 67(1), 2-17 (2000).
24. Ferrer IR, Liu D, Pinelli DF, Koehn BH, Stempora LL, Ford ML. CD40/CD154 blockade inhibits dendritic cell expression of inflammatory cytokines but not costimulatory molecules. J. Immunol. 189(9), 4387-4395 (2012).
25. Shen H, Goldstein DR. IL-6 and TNF-alpha synergistically inhibit allograft acceptance. J. Am. Soc. Nephrol. 20(5), 1032-1040 (2009).
26. Zhao X, Boenisch O, Yeung M et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am. J. Transplant. 12(1), 90-101 (2012).
27. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40(7), 1830-1835 (2010).
28. Ferrer IR, Wagener ME, Song M, Kirk AD, Larsen CP, Ford ML. Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade. Proc. Natl Acad. Sci. USA 108(51), 20701-20706 (2011).
29. Mackey MF, Wang Z, Eichelberg K, Germain RN. Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion. Eur. J. Immunol. 33(3), 779-789 (2003).
30. Johnson S, Zhan Y, Sutherland RM et al. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 30(2), 218-227 (2009).
31. Wood KJ, Bushell A, Jones ND. Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells. Immunol. Rev. 241(1), 119-132 (2011).
32. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193(11), 1311-1318 (2001).
33. Bilate AM, Lafaille JJ. Induced CD4(+)Foxp3(+) regulatory T cells in immune tolerance. Ann. Rev. Immunol. 30, 733-758 (2012).
34. Haribhai D, Williams JB, Jia S et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 35(1), 109-122 (2011).
35. Dodd-O JM, Lendermon EA, Miller HL et al. CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant. Am. J. Transplant. 11(9), 1815-1824 (2011).
36. Ochando JC, Homma C, Yang Y et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7(6), 652-662 (2006).
37. Zhang N, Schroppel B, Lal G et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 30(3), 458-469 (2009).
38. Warren KJ, Iwami D, Harris DG, Bromberg JS, Burrell BE. Laminins affect T cell trafficking and allograft fate. J. Clin. Invest. 124(5), 2204-2218 (2014).
39. Francis RS, Feng G, Tha-In T, Lyons IS, Wood KJ, Bushell A. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur. J. Immunol. 41(3), 726-738 (2011).
40. Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J. Immunol. 178(2), 671-682 (2007).
41. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297(5589), 2060-2063 (2002).
42. Sun JC, Bevan MJ. Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J. Immunol. 172(6), 3385-3389 (2004).
43. Lee BO, Hartson L, Randall TD. CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J. Exp. Med. 198(11), 1759-1764 (2003).
44. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am. J. Transplant. 10(3), 464-471 (2010).
45. Chen J, Yin H, Xu J et al. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am. J. Transplant. 13(9), 2280-2292 (2013).
46. Burns AM, Ma L, Li Y et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J. Immunol. 182(3), 1314-1324 (2009).
47. Page EK, Page AJ, Kwun J et al. Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am. J. Transplant. 12(9), 2395-2405 (2012).
48. Kim EJ, Kwun J, Gibby AC et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am. J. Transplant. 14(1), 59-69 (2014).
49. Monk NJ, Hargreaves RE, Marsh JE et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat. Med. 9(10), 1275-1280 (2003).
50. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat. Med. 9(2), 206-212 (2003).
51. Woelbing F, Kostka SL, Moelle K et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J. Exp. Med. 203(1), 177-188 (2006).
52. Starbeck-Miller GR, Badovinac VP, Barber DL, Harty JT. Cutting edge: Expression of FcgammaRIIB tempers memory CD8 T cell function in vivo. J. Immunol. 192(1), 35-39 (2014).
53. Ferrant JL, Benjamin CD, Cutler AH et al. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 16(11), 1583-1594 (2004).
54. Daley SR, Cobbold SP, Waldmann H. Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. Am. J. Transplant. 8(11), 2265-2271 (2008).
55. Xie JH, Yamniuk AP, Borowski V et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J. Immunol. 192(9), 4083-4092 (2014).
56. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23(1), 41-51 (2005).
57. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000).
58. Baudino L, Shinohara Y, Nimmerjahn F et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181(9), 6664-6669 (2008).
59. Pinelli DF, Wagener ME, Liu D et al. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3 iTreg in the absence and presence of CTLA-4 Ig. Am. J. Transplant. 13(11), 3021-3030 (2013).
60. Pearson TC, Trambley J, Odom K et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74(7), 933-940 (2002).
61. Adams AB, Shirasugi N, Jones TR et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174(1), 542-550 (2005).
62. Thompson P, Cardona K, Russell M et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am. J. Transplant. 11(5), 947-957 (2011).
63. Badell IR, Thompson PW, Turner AP et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am. J. Transplant. 12(1), 126-135 (2012).
64. Badell IR, Russell MC, Cardona K et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am. J. Transplant. 12(7), 1918-1923 (2012).
65. Lowe M, Badell IR, Thompson P et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am. J. Transplant. 12(8), 2079-2087 (2012).
66. Watanabe M, Yamashita K, Suzuki T et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am. J. Transplant. 13(8), 1976-1988 (2013).
67. Aoyagi T, Yamashita K, Suzuki T et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am. J. Transplant. 9(8), 1732-1741 (2009).
68. Okimura K, Maeta K, Kobayashi N et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive Effects. Am. J. Transplant. 14(6), 1290-1299 (2014).
69. Goldwater R, Keirns J, Blahunka P et al. A Phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am. J. Transplant. 13(4), 1040-1046 (2013).
70. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15(8), 541-555 (2014).
71. Pluvinet R, Petriz J, Torras J et al. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 104(12), 3642-3646 (2004).
72. Zheng X, Suzuki M, Zhang X et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res. Ther. 12(1), R13 (2010).
73. Ripoll E, Pluvinet R, Torras J et al. In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection. Gene Ther. 18(10), 945-952 (2011).
74. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 12(11), 967-977 (2013).
75. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789-8794 (1997).
76. Haanstra KG, Ringers J, Sick EA et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 75(5), 637-643 (2003).
77. Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: a Phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12(3), 630-639 (2012).
78. Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12(1), 210-217 (2012).
79. Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 171(7), 3348-3352 (2003).
80. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. J. Clin. Invest. 123(2), 580-593 (2013).
81. Riella LV, Liu T, Yang J et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am. J. Transplant. 12(4), 846-855 (2012).
82. Wojciechowski D, Vincenti F. Belatacept in kidney transplantation Curr. Opin. Organ Transpl. 17(6), 640-647 (2012).